Our Happy Clients
Alectinib, commonly known as Alecensa, is prescribed to treat certain types of non-small cell lung cancer (NSCLC). Specifically, it is used to treat NSCLC that has spread to other parts of the body (metastatic) and has an ALK gene rearrangement. This medication works by inhibiting the activity of the protein ALK abnormally overexpressed by cancer cells, helping to stop their growth and spread. Alectinib is taken orally, usually twice daily, and may cause side effects such as nausea, diarrhea, constipation, fatigue, and muscle or joint pain. Pregnant women should not take alectinib, and patients should consult their doctor to discuss the potential risks and benefits of using this medication.
It has been FDA approved for the treatment of non-small cell lung cancer (NSCLC) patients with tumours that are anaplastic lymphoma kinase (ALK)-positive. Alecensa is an oral, highly selective, central nervous system-active medicine. This tyrosine kinase inhibitor works by inhibiting signaling within cancer cells, preventing growth and survival. Alecensa targets cancer cells' ALK fusion proteins.
Product Delivery is a customer-centric approach to defining.
Product Delivery is a customer-centric approach to defining.
Product Delivery is a customer-centric approach to defining.